Novartis
Swiss-American multinational pharmaceutical corporation
NOVN SIX Swiss · home listing
NVS NYSE
ISIN CH0012005267 SEC CIK 1114448 LEI 5493007HIVTX6SY6XD66
Follow Novartis
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $54.5B | $14B |
| FY24 | $50.3B | $11.9B |
| FY23 | $45.4B | $14.9B |
| FY22 | $42.2B | $7B |
| FY21 | $42.8B | $24B |
| FY20 | $48.7B | $8.1B |
| FY19 | $47.5B | $11.7B |
| FY18 | $44.8B | $12.6B |
| FY17 | $42.4B | $7.7B |
| FY16 | $48.5B | $6.7B |
| FY15 | $49.4B | $17.8B |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 78.8% | 32.4% | 25.6% |
| FY24 | 77.3% | 28.9% | 23.7% |
| FY23 | 75.2% | 21.5% | 32.7% |
| FY22 | 75.5% | 18.8% | 16.5% |
| FY21 | 75.4% | 23.5% | 56.1% |
| FY20 | 71.5% | 20.9% | 16.6% |
| FY19 | 72.1% | 19.1% | 24.7% |
| FY18 | 70.5% | 18.7% | 28.1% |
| FY17 | 70.2% | 20.5% | 18.2% |
| FY16 | 65.8% | 17% | 13.8% |
| FY15 | 66.7% | 18.2% | 36% |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $17.6B |
| FY24 | $16.3B |
| FY23 | $13.4B |
| FY22 | $13.3B |
| FY21 | $14B |
| FY20 | $12.4B |
| FY19 | $12.2B |
| FY18 | $13B |
| FY17 | $11.3B |
| FY16 | $9.6B |
| FY15 | $9.5B |
| FY14 | - |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $7.8B | $9.2B |
| FY24 | $7.6B | $8.3B |
| FY23 | $7.3B | $8.7B |
| FY22 | $7.5B | $10.7B |
| FY21 | $7.4B | $3.1B |
| FY20 | $7B | $2.8B |
| FY19 | $6.6B | $5.5B |
| FY18 | $7B | $2B |
| FY17 | $6.5B | $5.5B |
| FY16 | $6.5B | $1.1B |
| FY15 | $6.6B | $6.1B |
| FY14 | - | - |
- Novartis
- Healthcare median
Show the numbers
| Year | Novartis | Healthcare median |
|---|---|---|
| FY25 | 25.6% | −30.6% |
| FY24 | 23.7% | −47% |
| FY23 | 32.7% | −58% |
| FY22 | 16.5% | −80.4% |
| FY21 | 56.1% | −71.9% |
| FY20 | 16.6% | −62.2% |
| FY19 | 24.7% | −46.3% |
| FY18 | 28.1% | −49.6% |
| FY17 | 18.2% | −45.9% |
| FY16 | 13.8% | −36% |
| FY15 | 36% | −38.4% |
| FY14 | - | −35.5% |